HOUSTON, TX - March 13, 2025 (NEWMEDIAWIRE) - Neutra Life Sciences, the Site Management Organization of Neutra Corp (OTC:NTRR), is comprised of clinical research sites that play a vital role in the advancement of medicine, serving as the foundation for groundbreaking treatments, innovative therapies, and life-saving interventions. These specialized facilities, staffed by dedicated healthcare professionals and researchers, are where new medical discoveries transition from theory to reality, shaping the future of patient care.

Clinical research sites conduct trials that evaluate the safety, immunogenicity and efficacy of new drugs, medical devices, and treatment protocols before they reach the general public. By working closely with pharmaceutical companies, biotechnology firms, and regulatory agencies, these sites help ensure that the latest medical advancements meet rigorous quality and safety standards.

“Without clinical research sites, the progress of medical science would come to a standstill,” said Sydney Jim, President and CEO of Neutra Corp. “These facilities are where innovation meets patient care, bringing hope to millions who depend on new and improved medications, treatments and medical devices.”

Patients who participate in clinical trials gain access to cutting-edge treatments before they become widely available. These studies offer potential health benefits and contribute to the greater good by advancing scientific knowledge and improving medical care for future generations.

Clinical research sites also play a crucial role in ensuring diversity and inclusivity in medical studies. By enrolling participants from diverse backgrounds, researchers can better understand how treatments affect different populations, leading to more effective and equitable healthcare solutions.

Neutra Life Sciences has solidified a joint venture partnership with Pediatric Center, its Pilot Program clinical research site. Despite being fully operational for only one quarter, Neutra’s Pilot Program Clinical Research Site secured multiple clinical trial contracts in mid-Q3 2024 to the end of 2024. This demonstrated the success of the program efforts and the rapid and strong growth potential in the industry. With multiple contracts awarded, the company anticipates ongoing revenue contributions, each varying in revenue value and with multiple in the potential six-figure range. This collaboration aims to advance pediatric clinical research, helping to ensure that children have access to the most recent medical innovations in a safe and supportive environment. The partnership will focus on potential groundbreaking therapies tailored to pediatric patients, addressing unmet medical needs and seeking to improve treatment outcomes for young patients.

As the demand for new therapies continues to grow, clinical research sites remain at the forefront of medical innovation. Their dedication to scientific integrity, patient safety, and groundbreaking research ensures that the future of medicine remains bright.

For more information about the role of clinical research sites in advancing medicine, or to learn how to participate in a clinical trial, please contact Neutra Life Sciences via phone 281-598-0200 or email at info@neutralifesciences.com.

About Neutra Corp

Neutra Corp is a health and wellness company dedicated to advancing life sciences, clinical research, and innovative consumer health solutions. With a diversified portfolio, Neutra Corp focuses on life sciences technology, clinical research, and high-quality wellness products designed to support overall health and well-being.

Committed to empowering individuals with the tools and knowledge needed to make informed healthcare decisions, Neutra Corp integrates cutting-edge research with real-world applications. Its expansion into life sciences and clinical research reinforces its mission to drive innovation in healthcare, while its wellness product line provides natural solutions for consumers seeking alternative wellness options.

Through strategic acquisitions and partnerships, Neutra Corp continues to grow its impact in the life sciences and health sectors, bridging the gap between research, technology, and consumer wellness. For investing, information and performance data, please visit https://www.neutrainc.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, a description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

View the original release on www.newmediawire.com

COMTEX_463573494/2549/2025-03-13T10:42:37